Female Contraception - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 89 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Contraception - Pipeline Review, H2 2016, provides an overview of the Female Contraception (Women's Health) pipeline landscape.

Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization and natural methods. Contraception generally work by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertilized egg from implanting in the uterus (hormones).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Contraception - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Female Contraception (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Contraception (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 5, 2, 6 and 5 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 1 and 2 molecules, respectively.

Female Contraception (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Contraception (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Female Contraception (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Contraception (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Female Contraception (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Female Contraception (Women's Health)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Female Contraception (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Female Contraception (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Female Contraception Overview 9
Therapeutics Development 10
Pipeline Products for Female Contraception - Overview 10
Pipeline Products for Female Contraception - Comparative Analysis 11
Female Contraception - Therapeutics under Development by Companies 12
Female Contraception - Therapeutics under Investigation by Universities/Institutes 13
Female Contraception - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Female Contraception - Products under Development by Companies 17
Female Contraception - Products under Investigation by Universities/Institutes 19
Female Contraception - Companies Involved in Therapeutics Development 20
Addex Therapeutics Ltd 20
Agile Therapeutics Inc 21
ANI Pharmaceuticals Inc 22
Bayer AG 23
Evofem Inc 24
Hervana Ltd 25
Mithra Pharmaceuticals SA 26
Orbis Biosciences Inc 27
Teva Pharmaceutical Industries Ltd 28
Viramal Ltd 29
Female Contraception - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
(anastrozole + levonorgestrel) - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
(drospirenone + estetrol) - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
(estradiol acetate + prasterone + progesterone) - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
(estradiol acetate + segesterone acetate) - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
ADX-68693 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
AG-200 ER - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
AG-200 SP - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
AG-20015 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
AG-890 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Amphora - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
BAY-1007626 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
drospirenone - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Drug for Female Contraception - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
EC-508 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Estetrol - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
etonogestrel ER - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
EVE-106 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
LJ-102 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Monoclonal Antibody Conjugates for Female Contraception - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
NOV-1003 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
S-003296 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
S-0101255 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Small Molecule 2 for Fertility Control - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Small Molecule for Female Contraception - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Small Molecule to Target Progesterone Receptor for Female Contraception - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Small Molecule to Target Progesterone Receptor for Fertility Control - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Synthetic Peptides for Female Contraception - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
TV-46046 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Female Contraception - Dormant Projects 77
Female Contraception - Discontinued Products 79
Female Contraception - Product Development Milestones 80
Featured News & Press Releases 80
Nov 07, 2016: Agile Therapeutics Announces Completion of Subject Visits for Twirla Phase 3 SECURE Clinical Trial 80
Sep 23, 2016: Mithra Pharmaceuticals: Phase III Clinical Study for Estelle in US Launched with first Randomized Patient 80
Sep 20, 2016: Addex collaborators publish new data on negative allosteric modulator ADX68693 80
Jul 22, 2016: Green Light From FDA For The Launch Of Estelle (E4/Drsp) Phase III Study In The United States 81
Jul 20, 2016: Canada Approves Clinical Trial Application For Estelle (E4/DRSP) PhasePhase III Study 82
Jul 12, 2016: Agile Therapeutics Announces Plans to Advance Contraceptive Pipeline 82
Jun 30, 2016: First Patient Screened For The European Product Candidate Estelle (E4/Drsp) Phase III Clinical Study 83
Jun 16, 2016: Agile Therapeutics Announces Issuance of Patent for Progestin Patch Designs 83
Apr 05, 2016: FDA Feedback On Spa Estelle: A New Step Closer To The Launch Of Estelle Phase III Pivotal Clinical Studies 83
Apr 01, 2016: Topline Results Of Food Effect Study Of The Product Candidate Estelle, The New Combined Oral Contraceptive Composed Of 15 mg Of Estetrol (E4) And 3 mg Of Drospirenone 84
Mar 24, 2016: Already 4 European Countries Fully Approved Protocol Of MIT-ES001-C301 Estelle Phase III Clinical Study 84
Oct 19, 2015: Agile Therapeutics Announces Completion of Patient Enrollment in Twirla Phase 3 SECURE Clinical Trial 85
Oct 19, 2015: Agile Therapeutics Announces Completion of Patient Enrollment in Twirla Phase 3 SECURE Clinical Trial 85
Sep 22, 2015: Evofem Announces FDA Acceptance of New Drug Application for Amphora as a Contraceptive 86
Aug 31, 2015: Agile Therapeutics Announces Completion of Patient Recruitment in Twirla Phase 3 SECURE Clinical Trial 86
Appendix 88
Methodology 88
Coverage 88
Secondary Research 88
Primary Research 88
Expert Panel Validation 88
Contact Us 88
Disclaimer 89

List of Tables

Number of Products under Development for Female Contraception, H2 2016 10
Number of Products under Development for Female Contraception - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 15
Comparative Analysis by Early Stage Development, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 (Contd..1) 18
Products under Investigation by Universities/Institutes, H2 2016 19
Female Contraception - Pipeline by Addex Therapeutics Ltd, H2 2016 20
Female Contraception - Pipeline by Agile Therapeutics Inc, H2 2016 21
Female Contraception - Pipeline by ANI Pharmaceuticals Inc, H2 2016 22
Female Contraception - Pipeline by Bayer AG, H2 2016 23
Female Contraception - Pipeline by Evofem Inc, H2 2016 24
Female Contraception - Pipeline by Hervana Ltd, H2 2016 25
Female Contraception - Pipeline by Mithra Pharmaceuticals SA, H2 2016 26
Female Contraception - Pipeline by Orbis Biosciences Inc, H2 2016 27
Female Contraception - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 28
Female Contraception - Pipeline by Viramal Ltd, H2 2016 29
Assessment by Monotherapy Products, H2 2016 30
Assessment by Combination Products, H2 2016 31
Number of Products by Stage and Target, H2 2016 33
Number of Products by Stage and Mechanism of Action, H2 2016 35
Number of Products by Stage and Route of Administration, H2 2016 37
Number of Products by Stage and Molecule Type, H2 2016 39
Female Contraception - Dormant Projects, H2 2016 77
Female Contraception - Dormant Projects (Contd..1), H2 2016 78
Female Contraception - Discontinued Products, H2 2016 79